6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients

Gastroenterology

Volumn 125, Issue 2, 2003, Pages 298-303

  Dubinsky, Marla C ^a   Vasiliauskas, Eric A ^a   Singh, Hardeep ^a   Abreu, Maria T ^a   Papadakis, Kostas A ^a   Tran, Tram ^a   Martin, Paul ^a   Vierling, John M ^a   Geller, Stephen A ^a   Targan, Stephan R ^a   Poordad, Fred F ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISONE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HYPERPLASIA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOCYTOPENIA;

EID: 0043168014     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00938-7     Document Type: Article

References (13)

1. Pearson DC, May GR, Frick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995;123:132-142.
2. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database of Systematic Reviews 2000:1.
3. Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. An open label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patient resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001;7:181-189.
4. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine (6-TG): a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003;98:1058-1063.
5. Herlinger KR, Kreisel W, Schwab M, Fischer C, Scholmerich J, Fleig WE, Rulh A, Reinshagen M, Metzler J, Fellerman K, Stange EF. Open prospective trial on 6-thiogunaine for chronic active Crohn's disease (abstr). Gastroenterology 2002;122:A432.
6. De Jong DJ, Derijks UJ, Jansen JBMJ, Hooymans PM, Mulder CJJ. 6-Thioguanine in azathioprine intolerant patients (abstr). Gastroenterology 2002;122:A432.
7. The Children's Cancer Group, Stork LC, Erdmaru G, Adamson P, Bostrom B, Matloub YH, Holcenberg I, Blake M, Kelleher JF, Masterson M, Ettinger RS, Sacher HN, Gaynon PS. Oral 6-thioguanine (TG) causes relatively mild and reversible hepatic venoocclusive disease (VOD) (abstr). J Ped Hematol Oncol 1998;20: A672.
8. Stork LC, Broxson EH, Sather H, Gaynon P, Matloub YH, Yanosfsky. R, Sorrell A, Wells L, Masterson M, Hutchinson RJ, Blake M, Sokol RJ. Oral 6-thioguanine causes late onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukemia (abstr). Gastroenterology 2002;122:A833.
9. Shepherd P, Harrison DJ. Idiopathic portal hypertension associated with cytotoxic drugs. J Clin Pathol 1990;43:206-210.
10. Shepherd PCA, Fooks J, Gray R, Allan NC. Thioguanine used in maintenance therapy of chronic myeloid leukemia causes noncirrhotic portal hypertension. Br J Haematol 1991;79:185-192.
11. Key NS, Kelly PM, Emerson PM, Chapman RW, Allan NC, McGee JO. Oesophageal varices associated with bisulphan-thioguanine combination therapy for chronic myeloid leukemia. Lancet 1987;2:1050-1052.
12. Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in haematologic disorders: a possible response to obliterative portal venopathy. Medicine 1980;59:367-379.
13. Shastri S, Dubinsky MC, Poordad FF, Vasiliauskas EA, Geller SA. Nodular hyperplasia of the liver (Sabourin lesion) occurring with inflammatory bowel diseases in association with 6-thiogunaine therapy (abstr). Am J Clin Pathol 2002;118:631.